Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315143 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL25985158 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL25988942 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL5800481 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL25985044 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL25985131 | 0.80 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL3582508 | 0.78 | TRPA1 (0.32) | — | |
| SCHEMBL3575502 | 0.78 | BTK (0.42) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL24821867 | 0.77 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL12493050 | 0.77 | BTK (0.44) | BTKGAAEPHX1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. | 2007-06-14 | — | — | US | disclosed |
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1399443-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003087098-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | BTK 3162/4885GAA 3702/4885EPHX1 3799/4885 |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | NRDC, NUCB2, NISCH | BTK 2825/4885GAA 4056/4885EPHX1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.